# Convergent Therapeutics, Inc.

> Convergent Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing next-generation targeted radiotherapies for cancer. Its lead candidate, CONV01-α, is a PSMA-targeted monoclonal antibody linked to the alpha-emitting radioisotope actinium-225, designed to deliver tumor-killing radiation to metastatic castration-resistant prostate cancer while sparing healthy tissue. The technology, pioneered in the lab of PSMA-targeting pioneer Dr. Neil Bander and licensed from Cornell University, is led by oncologist Dr. Philip Kantoff.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Philip Kantoff (Co-Founder & Chief Executive Officer), Neil Bander (Co-Founder & Senior Scientific Advisor)
- **Team size:** ~36 employees
- **Products:** CONV01-α (Ac-225 rosopatamab tetraxetan), Dual-targeted radionuclide therapy platform
- **Notable:** Closed a $90 million Series A in May 2023 led by OrbiMed and RA Capital Management with participation from Invus., Received FDA clearance of its IND application for CONV01-α in 2024., Treated its first patient in the Phase 2 CONVERGE-01 trial in 2024.

## Products & services

- **CONV01-α (Ac-225 rosopatamab tetraxetan)** — Lead clinical candidate: a PSMA-targeted monoclonal antibody conjugated to the alpha-emitting radioisotope actinium-225, designed to deliver potent tumor-killing alpha radiation to metastatic castration-resistant prostate cancer while reducing off-tumor toxicity such as renal damage and xerostomia.
- **Dual-targeted radionuclide therapy platform** — A proprietary radioantibody platform developed in the Bander Lab and licensed from Cornell University, applying PSMA-targeting antibodies and alpha-emitting payloads to prostate cancer and other solid tumors.

## Achievements

- Closed a $90 million Series A in May 2023 led by OrbiMed and RA Capital Management with participation from Invus.
- Received FDA clearance of its IND application for CONV01-α in 2024.
- Treated its first patient in the Phase 2 CONVERGE-01 trial in 2024.
- Secured multiple actinium-225 supply agreements (Cardinal Health, IONETIX, NorthStar) to de-risk isotope supply.
- Presented what it describes as the largest prospective Phase 2 dataset for an alpha radiopharmaceutical in Lu-PSMA-exposed mCRPC at ASCO 2026, with no high-grade xerostomia and no renal toxicity reported.

## Latest updates

- **2026-06** — Announced positive Phase 2 CONVERGE-01 Part 3 data at ASCO 2026 showing anti-tumor activity, durability, and favorable tolerability for CONV01-α in Lu-PSMA-exposed mCRPC; supports advancing toward a pivotal Phase 3 study.
- **2024-11** — Received first shipments of non-carrier-added actinium-225 from Cardinal Health to support the CONVERGE-01 Phase 2 trial.
- **2024-09** — Latest reported financing (Series A) noted at ~$40M tranche; first patient treated in Phase II trial and corporate updates announced.
- **2024** — FDA cleared the IND application for CONV01-α, a PSMA-targeted radioantibody.
- **2023-05** — Closed $90 million Series A financing led by OrbiMed and RA Capital Management.

## Links

- Website: https://convergentrx.com
- LinkedIn: https://www.linkedin.com/company/convergent-therapeutics
- Twitter/X: https://twitter.com/ConvergentRx

---

Profile page: https://yespress.io/convergent-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-19